Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur

British Journal of Haematology

Volumn 158, Issue 3, 2012, Pages 355-362

  Geisler, Christian H ^a   Kolstad, Arne ^b   Laurell, Anna ^c   Jerkeman, Mats ^d   Räty, Riikka ^e   Andersen, Niels S ^a   Pedersen, Lone B ^a   Eriksson, Mikael ^d   Nordström, Marie ^f   Kimby, Eva ^f   Bentzen, Hans ^g   Kuittinen, Outi ^h   Lauritzsen, Grete F ^b   Nilsson Ehle, Herman ⁱ   Ralfkiær, Elisabeth ^a   Ehinger, Mats ^d   Sundström, Christer ^c   Delabie, Jan ^b   Karjalainen Lindsberg, Marja Liisa ^e   Brown, Peter ^a   Elonen, Erkki ^e   Pedersen, Lars Møller ^j   Hansen, Per Boye ^j   Østenstad, Bjørn ^k   Ekanger, Roald ^l   Maisenhølder, Martin ^m   Fagerli, Unn Merete ⁿ   Matusik, Piotr ^o   Lindblom, Anders ^p   Fredén, Susanne ^q   Malmberg, Lena ^r   Hjorth, Martin ^s   Rommel, Franz ^t   Väärt, Jaan ^u   Malmér, Beatrice ^v   Vaktnäs, Johan ^w   more..

^a Rigshospitalet   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f KAROLINSKA INSTITUTE   (Sweden)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h OULU UNIVERSITY HOSPITAL   (Finland)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

ⁿ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^o BORÅS HOSPITAL   (Sweden)

^p MALMÖ UNIVERSITY   (Sweden)

^q Jönköping Hospital   (Sweden)

^r Karlstad Hospital   (Sweden)

^s Lidkoping Hospital   (Sweden)

^t Norrkoping Hospital   (Sweden)

^u Skövde Hospital   (Sweden)

^v UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^w VARBERG HOSPITAL   (Sweden)

more..

Author keywords

Autologous stem cell transplant; High dose AraC; Mantle cell lymphoma; Pre emptive therapy; Rituximab

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; KI 67 ANTIGEN; MELPHALAN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CLINICAL OBSERVATION; DENMARK; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FINLAND; FOLLOW UP; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MCL PROGNOSTIC INDEX; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORWAY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; SWEDEN; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; PROGNOSIS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84863822702     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09174.x     Document Type: Article

References (33)

1. Andersen, N.S., Pedersen, L., Elonen, E., Johnson, A., Kolstad, A., Franssila, K., Langholm, R., Ralfkiaer, E., Akerman, M., Eriksson, M., Kuittinen, O. & Geisler, C.H. for the Nordic Lymphoma Group (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. European Journal of Haematology, 71, 73-80.
2. Andersen, N.S., Pedersen, L.B., Laurel, A., Elonen, E., Kolstad, A., Boesen, A.M., Pedersen, L.M., Lauritzsen, G.F., Ekanger, R., Nilsson-Ehle, H., Nordström, M., Fredén, S., Jerkeman, M., Eriksson, M., Väärt, J., Malmer, B. & Geisler, C.H. (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Journal of Clinical Oncology, 27, 4365-4370.
3. Budde, L.E., Guthrie, K.A., Till, B.G., Press, O.W., Chauncey, T.R., Pagel, J.M., Petersdorf, S.H., Bensinger, W.I., Holmberg, L.A., Shustov, A.R., Green, D.J., Maloney, D.G. & Gopal, A.K. (2011) Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. Journal of Clinical Oncology, 29, 3023-3029.
4. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244-1253.
5. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
6. Delfau-Larue, M., Hoster, E., Berger, F., Jardin, F., Briere, J., Feugier, P., Haioun, C., Ribrag, V., Salles, G., Thieblemont, C., Casasnovas, O., Unterhalt, M., Dreyling, M., Pott, C., MacIntyre, E. & Hermine, O. (2011) High-dose Aracytine in induction might counteract the adverse prognostic value of gene copy number alteration in autografted MCL patients. An EUMCL Network study. Annals of Oncology, 22, Suppl. 4: 162. (11th International Conference on Malignant Lymphoma, abstract 234).
7. Determann, O., Hoster, E., Ott, G., Bernd, H.W., Loddenkemper, C., Hansmann, L.M., Barth, T.E., Unterhalt, M., Hiddemann, W., Dreyling, M. & Klapper, W. (2008) European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood, 111, 2385-2387.
8. Dietrich, S., Tielesch, B., Rieger, M., Nickelsen, M., Pott, C., Witzens-Harig, M., Kneba, M., Schmitz, N., Ho, A.D. & Dreger, P. (2011) Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer, 117, 1901-1910.
9. Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin-Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. & Hiddemann, W. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677-2684.
10. Epner, E.M., Unger, J., Miller, T., Rimzsa, L., Spier, C., Leblanc, M. & Fisher, R. (2007) A multi center trial of hypercvad+rituxan in patients with newly diagnosed mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts), 110, Abstract 387.
11. Garcia, M., Romaguera, J.E., Inamdar, K.V., Rassidakis, G.Z. & Medeiros, L.J. (2009) Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer, 115, 1041-1048.
12. Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundström, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P. & Elonen, E. for the Nordic Lymphoma Group. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687-2693.
13. Geisler, C.H., Kolstad, A., Laurell, A., Räty, R., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A.M., Nilsson-Ehle, H., Kuittinen, O., Lauritzsen, G.F., Ralfkiaer, E., Ehinger, M., Sundström, C., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P. & Elonen, E. for the Nordic Lymphoma Group. (2010) The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 115, 1530-1533.
14. Gianni, A.M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Rambaldi, A., Cortelazzo, S., Patti, C., Parvis, G., Benedetti, F., Capria, S., Corradini, P., Tarella, C. & Barbui, T. (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood, 102, 749-755.
15. Griffiths, R., Mikhael, J., Gleeson, M., Danese, M. & Dreyling, M. (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood, 118, 4808-4816.
16. Hermine, O., Hoster, E., Walewski, J., Ribrag, V., Brousse, N., Thieblemont, C., Bouabdallah, R., Stilgenbauer, S., Feugier, P., Forstpointner, R., Haioun, C., Kneba, M., Hanel, M., Casasnovas, R-O., Finke, J., Hallek, M., Wandt, H., Bosly, A., Klapper, W., Gisselbrecht, C., Coiffier, B., Hiddemann, W., Unterhalt, M. & Dreyling, M.H. (2010) Alternating courses of 3 x CHOP and 3 x DHAP plus rituximab followed by high-dose AraC containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to six courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts), 116, Abstract 110.
17. Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wörmann, B., Trümper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. & Dreyling, M. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511-518.
18. Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H.C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wörmann, B., Ludwig, W.D., Dührsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W. & Unterhalt, M. & German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111, 558-565.
19. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. & Shipp, M.A. (2005) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 1288-1294.
20. Katzenberger, T., Petzoldt, C., Höller, S., Mäder, U., Kalla, J., Adam, P., Ott, M.M., Müller-Hermelink, H.K., Rosenwald, A. & Ott, G. (2006) The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood, 107, 3407.
21. Khouri, I.F., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., Hagemeister, F., Samuels, B., Rodriguez, A., Giralt, S., Younes, A., Przepiorka, D., Claxton, D., Cabanillas, F. & Champlin, R. (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Journal of Clinical Oncology, 27, 511-518.
22. Klapper, W., Hoster, E., Determann, O., Oschlies, I., van der Laak, J., Berger, F., Bernd, H.W., Cabeçadas, J., Campo, E., Cogliatti, S., Hansmann, M.L., Kluin, P.M., Kodet, R., Krivolapov, Y.A., Loddenkemper, C., Stein, H., Möller, P., Barth, T.E., Müller-Hermelink, K., Rosenwald, A., Ott, G., Pileri, S., Ralfkiaer, E., Rymkiewicz, G., van Krieken, J.H., Wacker, H.H., Unterhalt, M. & Hiddemann, W. & Dreyling M. for the European MCL Network (2009) Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology 2, 103-111.
23. Kluin-Nelemans, J.C., Hoster, E., Walewski, J., Stilgenbauer, S., Geisler, C. H., Gisselbrecht, C., Vehling-Kaiser, U., Doorduijn, J. K., Trneny, M., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Szymczyk, M., Hermine, O., Klapper, W., Hiddemann, W., Unterhalt, M. & Dreyling, M. H. (2011) R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alpha: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts), 118, Abstract 439.
24. Le Gouill, S., Thieblemont, C., Gyan, E., Tournilhac, O., Laurent, G., Damaj, G., Houot, R., Haioun, C., Gressin, R., Traverse-Glehen, A., Bene, M.C., Macintyre, E., Delfau-Larue, M.-H., Lioure, B, Cartron, G., Moreau, P., Tilly, H., Caulet-Maugendre, S., Callanan, M. & Hermine, O. (2010) High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1758.
25. Lefrère, F., Delmer, A., Suzan, F., Levy, V., Belanger, C., Djabarri, M., Arnulf, B., Damaj, G., Maillard, N., Ribrag, V., Janvier, M., Sebban, C., Casasnovas, R.O., Bouabdallah, R., Dreyfus, F., Verkarre, V., Delabesse, E., Valensi, F., McIntyre, E., Brousse, N., Varet, B. & Hermine, O. (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia, 16, 587-593.
26. Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. & Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984-1992.
27. Pott, C., Hoster, E., Beldjord, K., Macintyre, E.A., Bottcher, S., Asnafi, V., Siebert, R., Plonquet, A., Callet-Bauchut, E., Ribrag, V., Klapper, W., Berger, F., Unterhalt, M., Kneba, M., Hiddemann, W., Dreyling, M.H., Hermine, O. & Delfau, M.-H. (2010) R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network. Blood, (ASH Annual Meeting Abstracts), 116, 965.
28. Räty, R., Franssila, K., Joensuu, H., Teerenhovi, L. & Elonen, E. (2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. European Journal of Haematology, 69, 11-20.
29. Romaguera, J.E., Fayad, L.E., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N.H., Wang, M., Beasley, V., Medeiros, L.J., Katz, R.L., Gagneja, H., Samuels, B.I., Smith, T.L. & Cabanillas, F.F. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose Methotrexate and Cytarabine. Journal of Clinical Oncology, 23, 7013-7023.
30. Romaguera, J.E., Fayad, L.E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M.A., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Cabanillas, F., Kantarjian, H., Kwak, L. & Wang, M. (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. British Journal of Haematology, 150, 200-208.
31. Swerdlow, S.H., Berger, F. & Isaacson, P.I. (2001) Mantle cell lymphoma. In: World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman ), pp. 168-170. IARC Press, Lyon, France.
32. Van 't Veer, M.B., De Jong, D., Mackenzie, M., Kluin-Nelemans, H.C., Van Oers, M.H., Zijlstra, J., Hagenbeek, A. & Van Putten, W.L. (2008) High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. British Journal of Haematology, 144, 524-530.
33. Weisenburger, D.D. & Armitage, J.O. (1996) Mantle cell lymphoma - an entity comes of age. Blood, 87, 4483-4494.